ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/IL-2 Fusion Protein TEV-56278

Also written as “TEV-56278”, “Intervention1:FXB0871” and “Intervention2:FXB0871”.

In Fosun Pharma’s pipeline, PD-1/IL-2. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 1, since Apr 7, 20262 company-led studies, 2 open or runningNext primary completion: May 26, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharmaits history only11 open or runningphase 1since Apr 7, 2026Apr 7, 2026Apr 23, 2030phase 1 · NCT07558200
Teva Pharmaceutical Industriesits history only11 open or runningphase 1since Jun 10, 2024Jun 10, 2024May 26, 2029phase 1 · NCT06480552

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2024First study: phase 1 study in Advanced Solid TumorsNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06480552 · 240 planned · United States, Canada
  2. Apr 7, 2026Fosun Pharma’s first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Fosun PharmaFosun Pharma · NCT07558200 · 138 planned · China

Ahead

  1. May 26, 2029Primary completion: phase 1 study in Advanced Solid TumorsTeva Pharmaceutical Industries · NCT06480552
  2. Apr 23, 2030Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungFosun Pharma · NCT07558200

TargetBeta

“PD-1/IL-2”the company's pipeline, read by Claude · source
“A recombinant fusion protein composed of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Daxokafusp AlfaSanofiphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07558200Carcinoma, Non-Small-Cell Lung · China1Not yet recruitingFosun PharmaApr 23, 2030138
NCT06480552Advanced Solid Tumors · United States, Canada1RecruitingTeva Pharmaceutical IndustriesMay 26, 2029240

How it is read

Names in the registry

  • “TEV-56278”, 1 entry
  • “Intervention1:FXB0871”, 1 entry
  • “Intervention2:FXB0871”, 1 entry
  • “Intervention3:FXB0871”, 1 entry
  • “Intervention4:FXB0871”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.